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Immunological cross talk betweenmucosal tissues such as the intestine and the lung is poorly defined during homeostasis and
disease. Here, we show that a low-dose infection with the intestinally restricted helminth parasite Trichuris muris results in the
production of Th1 cell-dependent gamma interferon (IFN-) andmyeloid cell-derived interleukin-10 (IL-10) in the lung without
causing overt airway pathology. This cross-mucosal immune response in the lung inhibits the development of papain-induced
allergic airway inflammation, an innate cell-mediated type 2 airway inflammatory disease. Thus, we identify convergent and
nonredundant roles of adaptive and innate immunity in mediating cross-mucosal suppression of type 2 airway inflammation
during low-dose helminth-induced intestinal inflammation. These results provide further insight in identifying novel intersect-
ing immune pathways elicited by gut-to-lung mucosal cross talk.
Barrier tissues such as the intestine and lungs that are exposedto the external environment are faced with the unique chal-
lenge of mounting protective immune responses against potential
pathogens while maintaining homeostasis and tolerance to harm-
less antigens and commensal organisms. Disruption of barrier
function and dysregulation of mucosal immune homeostasis are
characteristic of a variety of mucosal diseases such as inflamma-
tory bowel diseases and asthma (1–3). The mucosal immune sys-
tem is interconnected, as mucosal immunization at one site can
provide immunity at other mucosal sites (4, 5). This is further
highlighted by the challenges of administering protective vaccines
to populations that have heavy enteric pathogen burdens interfer-
ing with immunity, particularly in underdeveloped countries (6).
However, little is still known about how chronic inflammation
associated with infections at one barrier site influences mucosal
immune responses at other sites.
Immunological cross talk can occur between distinct mucosal
sites such as the lung and the intestine (7). For example, the intes-
tinal microbiota in early life has been shown to play a role in
determining susceptibility to asthma later in life (8, 9). As well,
there is evidence that trafficking of immune cells can occur di-
rectly between these organs; lung dendritic cells (DCs) have the
ability to prime and license lung-residing T cells to home toward
intestinal tissues via specific homing receptors (10). In addition,
interstitial pneumonia has been reported to occur inmouse mod-
els of chronic colitis (11) and a subset of inflammatory bowel
disease patients have been reported to exhibit extraintestinal in-
flammation in the lungs (12). However, whether this gut-lung
immune cross talk plays a physiological role in health and disease
still remains unclear.
Mucosal inflammatory diseases invariably involve the action of
a variety of CD4 T helper (Th) cell subsets differentiating in a
context-specific fashion, depending on the inflammatory milieu.
Gastrointestinal inflammation often involves pathogenic Th1 or
Th17 cell populations that mediate chronic inflammatory pro-
cesses (13). Conversely, Th2 cells play a major role in type 2 im-
mune responses in allergic respiratory diseases such as asthma (14,
15). Importantly, a given Th cell response can counteract the de-
velopment of other Th cell responses (16), and this balance of Th
cell differentiation plays a major role in determining immune ho-
meostasis or disease susceptibility. However, this Th cell-intrinsic
regulation is not as well understood in the context of mucosal
immune cross talk. Further, it has recently been shown that innate
cell populations, includingmyeloid cells and innate lymphoid cell
(ILC) subsets, also play an important role duringmucosal inflam-
mation (17–19). In this study, we directly investigate the gut-lung
immune axis by examining the effect of an intestinally restricted
helminth infection on the lung immune microenvironment and
its impact on the development of type 2 innate cell-mediated air-
way inflammation. We identify nonredundant, convergent adap-
tive, and innate immune processes bymodeling thismucosal cross
talk.
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MATERIALS AND METHODS
Ethics statement.Experiments were approved by theUniversity of British
Columbia (UBC) Animal Care Committee (ACC) (protocol number
A13-0010) and were in accordance with the Canadian Guidelines for An-
imal Research.
Mice andhelminth infections.C57BL/6J, GREAT [gamma interferon
(IFN-) reporter with endogenous poly(A) tail] (20), andRag1/mouse
strains were purchased from the Jackson Laboratory (Bar Harbor, ME).
Vert-X (C57BL/6 interleukin-10 [IL-10] enhanced green fluorescent pro-
tein [eGFP])mice were originally generated by Christopher Karp (21). All
mice were bred andmaintained in specific-pathogen-free animal facilities
at the Biomedical Research Centre. Propagation of Trichuris muris eggs
and infections were performed as previously described (22). Mice were
infected with 30 hand-counted, embryonatedT.muris eggs by oral gavage
to induce a low-dose intestinal infection over a period of 21 days. Sacri-
ficed mice were assessed for worm burdens by manually counting worms
in the ceca using a dissectingmicroscope.Worm antigenwas generated by
pooling live worms isolated from infected immunodeficient mice into
Dulbecco modified Eagle medium (DMEM) and incubating them for 4 h
at 37°C. The supernatant was then dialyzed in phosphate-buffered saline
(PBS) for 4 days and filter sterilized prior to quantification of total protein
using a bicinchoninic acid (BCA) assay.
Induction of acute allergic airway inflammation (AAI). Mice were
anesthetized under aerosolized isoflurane and immediately instilled with
10 g of papain from papaya latex (Sigma, St. Louis, MO) intranasally
(i.n.) in 40 l of sterile PBS on days 18, 19, and 20 post-infection with T.
muris. The day after the last instillation of papain, mice were injected
intraperitoneally (i.p.) with 2,2,2-tribromoethanol (Avertin; Sigma), tra-
cheas were cannulated, and bronchoalveolar lavages (BALs) were per-
formed using triplicates of 1 ml of sterile 10% fetal bovine serum in PBS.
BAL fluid was then red cell lysed using ammonium chloride buffer. Lung
tissue was digested in 200 U/ml collagenase type IV (Sigma) for 1 h, red
cell lysed, and centrifuged in a 30% Percoll solution to purify leukocytes.
BAL fluid and lung cells were analyzed by flow cytometry.
Ex vivo stimulation of lung cells. Following tissue digestion and Per-
coll enrichment as described above, lung cells were stimulated at 37°C and
4%CO2 for 4 hwith cell stimulation cocktail containing protein transport
inhibitors (eBioscience). Cells were then processed for intracellular cyto-
kine staining using an intracellular fixation and permeabilization buffer
set (eBioscience).
Antibodies and flow cytometry. Cell counts were determined via he-
mocytometer or with latex beads for BAL fluid samples. Sample process-
ing and intracellular cytokine staining were performed as previously
described (23). Fluorescein isothiocyanate (FITC)-conjugated anti-neu-
trophil Ly6B (7/4) was purchased fromAbcam (Cambridge,MA). Phyco-
erythrin (PE)-conjugated anti-Siglec F (E50-2440) and anti-CD25 (PC61)
and allophycocyanin (APC)-conjugated anti-Ly6G (1A8) were purchased
from BD Biosciences (San Jose, CA). FITC-conjugated anti-IL-10 (JES5-
16E3); PE-conjugated anti-CD4 (RM4-4) and anti-IL-5 (TRFK4); PE-
Cy7-conjugated anti-CD3e (2C11), anti-IFN- (XMG1.2), and anti-I-A/
I-E (major histocompatibility complex class II [MHC-II]) (M5/114.15.2);
peridinin chlorophyll protein (PerCP)-eFluor 710-conjugated anti-ST2
(RMST2-2); eFluor 450-conjugated anti-CD8a (53-6.7); APC-conjugated
anti-CD4 (GK1.5) and anti-F4/80 (BM8); and APC-eFluor 780-conju-
gated anti-Ly6C (HK1.4) and anti-B220 (RA3-6B2) were purchased from
eBioscience. FITC-conjugated anti-CD19 (1D3), anti-CD11b (M1/70),
anti-CD11c (N418), anti-Gr1 (RB6-8C5), anti-NK1.1 (PK136), anti-
Ter119 (Ter119), and anti-CD3e (2C11); Pacific Blue-conjugated anti-
CD45 (I3/2) and anti-CD11b (M1/70); and Alexa Fluor 647-conjugated
anti-CD11c (N418) and CD90.2 (30H12) were produced in-house by the
UBC AbLab. Data were acquired on an LSR II flow cytometer (BD Bio-
sciences) and analyzed with FlowJo software (TreeStar, San Carlos, CA).
RNA isolation and quantitative real-time PCR (qRT-PCR). Tissues
were mechanically homogenized using a bead basher, and RNA was ex-
tracted using the TRIzolmethod according to themanufacturer’s instruc-
tions (Ambion, Austin, TX). cDNA was generated using High-Capacity
cDNA reverse transcription kits according to the manufacturer’s instruc-
tions (Applied Biosystems, Foster City, CA). Quantitative PCR was per-
formed using the SYBR FAST master mix (Kapa Biosystems, Woburn,
MA) and SYBR green-optimized primer sets run on anABI 7900 real-time
PCR machine (Applied Biosystems). Threshold cycle (CT) values of all
genes measured in each sample were normalized relative to beta-actin
(Actb) gene expression. Primer sets are listed in Table 1.
ELISA. Standard sandwich enzyme-linked immunosorbent assay
(ELISA) of cytokines was performed using commercially available anti-
bodies (eBioscience). Plates were developed using 3,3=,5,5=-tetramethyl-
benzidine (TMB) substrate (Mandel Scientific, Guelph, ON, Canada), the
reaction was stopped with 1 N HCl, and plates were read at 450 nm on a
SpectraMax 384 plate reader (Molecular Devices, Sunnyvale, CA).
Histology. Lung lobes were fixed in buffered 4% paraformaldehyde
solution and embedded into paraffin blocks. Five-micrometer-thick sec-
tions were stained with periodic acid-Schiff (PAS) stain. Airways were
assessed for PAS staining as an indication of mucus hyperproduction.
PAS cells in the airways in each lung section were quantified.
Depletion of CD4 T cells.Mice were injected i.p. with 300 g puri-
fied anti-mouse CD4 (GK1.5) in PBS or with PBS alone on days 15 and 17
postinfection, prior to airway challenge. An isotype IgG control antibody
was not used sinceCD4depletion creates tolerance to anti-rat Ig responses
(24).
In vivo neutralization of IL-10 activity. T. muris-infected mice were
injected i.p. with 500 g purified anti-mouse IL-10 receptor (IL-10R) or
control IgG1 (Bio X Cell, New Hampshire) on day 6 postinfection and
then subsequently every 3 days until day 18, prior to airway challenge.
HDM model of asthma. For the first 3 days of airway sensitization,
mice were anesthetized under aerosolized isoflurane and intranasally in-
stilled with 100 g of house dust mite (HDM) antigen (Greer, Lenoir,
NC). On days 13 to 17 postsensitization, mice were intranasally chal-
lenged with 25 g of HDM antigen daily before sacrifice on day 18. BAL
fluid and tissues were processed as described above to assess airway dis-
ease.
Statistics.Data are presented asmeans standard errors of themeans
(SEM). Statistical significance between two groups was determined by the
Student t test while comparisons between 3 ormore groups weremade by
analysis of variance (ANOVA) with a Bonferroni post hoc test using
GraphPad Prism software. Results were considered statistically significant
with a P value of0.05 (*),0.01 (**), or0.001 (***).
TABLE 1 Gene expression primer sets
Primer
Sequence
Forward (5=–3=) Reverse (5=–3=)
Cd4 CTTCGCAGTTTGATCGTTTTGAT CCGGACTGAAGGTCACTTTGA
Ifng GGATGCATTCATGAGTATTGCC CCTTTTCCGCTTCCTGAGG
Il5 GATGAGGCTTCCTGTCCCTACTC TCGCCACACTTCTCTTTTTGG
Il10 CTGAAGACCCTCAGGATGCG TGGCCTTGTAGACACCTTGGTC
Tbx21 CAACAACCCCTTTGCCAAAG TCCCCCAAGCAGTTGACAGT
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RESULTS
Low-dose T. muris infection alters the lung immune microen-
vironment.To characterize the cross-mucosal effect of a localized
intestinal immune response, we employed the Trichuris muris
model of intestinal infection (25). T. muris infection is a powerful
model to study the development of protective Th2 cell-dependent
and nonprotective Th1 cell-mediated immune responses in vivo.
After 21 days of a low-dose infection, C57BL/6 mice develop an
adaptive anti-T. muris response, characterized by high levels of
Th1 cell-derived IFN-, resulting in a persistent worm burden
(Fig. 1A). We analyzed the distal mucosal lung tissue for changes
in cytokine gene expression by qRT-PCR and found no differ-
ences in genes for Th2 cell-associated cytokines, such as Il5, be-
tween control and T. muris-infected mice (Fig. 1B); however, we
found significantly increased expression of Ifng and Il10 in the
lungs of T. muris-infected mice compared to uninfected mice.
These changes in cytokine gene expression in the lungs of T.
muris-infected mice correlated with similar increases in IFN-
and IL-10 protein levels whenmeasured by ELISA of ex vivo-stim-
ulated lung cell cultures (Fig. 1C). From the lungs of T. muris-
infectedmice, only IFN-, but not IL-5 or IL-10, was detectable at
low levels in response to T. muris-specific antigen (Fig. 1D). De-
spite these changes in lung cytokine expression in T. muris-in-
fected mice, there was no evidence of inflammation or pathology
in the lungs of T. muris-infected mice compared to naive controls
by histology and based on total cells and cell composition in bron-
choalveolar lavage (BAL) fluid (Fig. 1E). Thus, a low-dose intes-
tinal immune response is sufficient to alter the lung immune mi-
croenvironment by upregulating IFN- and IL-10 expression
without causing overt lung tissue pathology.
Lung CD4 T cells increase IFN- production during low-
dose T. muris infection. To determine the cellular source of the
infection-induced IFN- and IL-10 in the lung, we performed ex
vivo culture stimulations of lung cells to characterize cytokine ex-
pression by key cell populations. As several recent studies have
identified populations of lung CD4 T cells that produce both
IFN- and IL-10 (26–28), we examined whether CD4 T cells
were the dominant source of these cytokines. Following stimula-
tion of lung cells with anti-CD3/CD28 antibodies, we found that a
significant frequency of lung CD4 T cells produced IFN-, with
the highest levels in mice infected with T. muris (Fig. 2A). In con-
trast, CD4 T cells produced low levels of IL-10 in the lungs of
either uninfected or T. muris-infected mice (Fig. 2B), and we ob-
served a negligible population of IFN-/IL-10 double-positive
CD4 T cells (data not shown). To better assess IL-10 expression
without cell stimulation, we performedfluorescence-activated cell
sorting of IFN- and IFN- CD4 T cells from the lungs of T.
muris-infected IFN- reporter (GREAT) mice (20) followed by
gene expression analysis ex vivo. We confirmed that IFN--pro-
ducingCD4T cells appeared to beTh1 cells that expressedTbx21
and Ifng but did not express increased levels of Il10 (Fig. 2C).
Although CD8 T cells have also been shown to produce IFN-
and IL-10 following viral infection of the lung, we failed to detect
differences in CD8 T cell-derived IFN- or IL-10 (data not
shown). Together, these results show that the intestinally re-
stricted T. muris infection results in a potent Th1 cell response in
the lungs but that CD4 T cells are likely not the main source of
IL-10.
Lung myeloid cells increase IL-10 expression during low-
dose T. muris infection. Since we saw no differences in T cell-
FIG1 Low-dose intestinal infectionwithT.muris alters the lung immunemicroenvironment. (A) Enumerated cecal wormburdens. (B) LungmRNAexpression
of Il5, Ifng, and Il10 normalized relative to Actb. (C) ELISA of IL-5, IFN-, and IL-10 from ex vivo unstimulated and polyclonally stimulated lung cell cultures.
(D) ELISA of IFN- from T. muris antigen (Ag)-stimulated lung cell cultures. (E) Lung histology visualized using20 magnification and total and differential
bronchoalveolar lavage (BAL) fluid counts. Data are means  SEM, pooled from 3 independent experiments (n 	 6 mice per group) (A to E). Sections are
representative of 3 independent experiments (E). Ctrl, control; Tm, T. muris infected; nd, not detected; Rel., relative.
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derived IL-10 levels, we hypothesized that innate cells were pro-
ducing IL-10 in the lungs of T. muris-infected mice. We therefore
characterized possible innate cellular sources of IL-10 induced in
the lungs of T. muris-infected mice ex vivo using a fluorescent
IL-10 reporter (Vert-X) (21)mouse strain crossed onto aRag1/
background. Compared to naive control mice, T. muris-infected
Rag1/ Vert-X mice had a significant increase in the frequency
and total number of IL-10 cells in the lung (Fig. 3A). There was a
significant expansion of CD11b CD11c myeloid cells produc-
ing IL-10 in T. muris-infected mice compared to uninfected con-
trols, while we saw no differences in IL-10 production between
CD11b CD11c populations in terms of absolute numbers (Fig.
3B). Further phenotypic analysis showed that lung IL-10 my-
eloid cells from T. muris-infected mice were predominantly
Ly6G Ly6C (Fig. 3C) and were largely negative for surface
markers associated with alveolar and interstitial macrophages
such as Siglec F and F4/80 (Fig. 3D). Lung IL-10 myeloid cells
from T. muris-infectedmice also had a reduction inMHC-II (Fig.
3E). Upon examining individual cell types for IL-10 production,
we found that lungCD11cB220 cells, resembling plasmacytoid
DCs (pDCs), had the most significant increase in IL-10 produc-
tion duringT.muris infection (Fig. 3F). These data show that lung
IL-10 myeloid cells that are predominantly CD11b CD11c,
including a subset of pDC-like cells, emerge during low-dose T.
muris intestinal infection, independently of adaptive immunity.
Low-dose T. muris infection protects against innate immu-
nity-mediated AAI. We hypothesized that the immunological
changes in the lung elicited by our low-dose intestinal helminth
infection could affect the development of type 2 inflammatory
responses, such as allergic airway inflammation (AAI). To directly
address this, C57BL/6 mice were infected with a low dose of T.
muris and challenged with papain intranasally (Fig. 4A). Acute
airway challenge with papain causes an early activation of ILC2
cells that promotes eosinophil recruitment and mucus hyperpro-
duction (29). Papain treatment did not affect infection dynamics,
as low-dose infections persisted following papain exposure (Fig. 4B).
BAL fluid analysis showed that papain induced an influx of in-
flammatory cells in the airways of uninfected mice (Fig. 4C). In
contrast,mice infectedwithT.muris had a significant reduction in
airway cell influx after papain challenge. While uninfected mice
displayed airway eosinophilia after papain challenge, infected
mice were significantly protected from eosinophil infiltration.
Further, T. muris-infected mice had a reduction in lung tissue
eosinophils after papain challenge. Papain-induced goblet cell hy-
perplasia and mucus production were also reduced in T. muris-
infected mice (Fig. 4D). Expression of the Th2 cell-associated cy-
tokine gene Il5 in the lung was increased in control mice but was
not induced in T. muris-infectedmice after papain challenge, cor-
relating with the reduction in eosinophil recruitment to the air-
ways and lungs (Fig. 4E). Consistent with our previous results, T.
muris-infectedmice had significantly increased expression of lung
Ifng and Il10 after papain airway challenge. Despite this T. muris-
mediated protection from papain-induced AAI, we found no dif-
ferences in the induction of lung ILC2 cells in response to papain
in terms of absolute numbers (Fig. 4F). Additionally, the capacity
for lung ILC2 cells to produce IL-13 in response to papain was
unaffected by T. muris infection (Fig. 4G). Thus, changes in the
lung immune microenvironment during low-dose intestinal in-
fection with T. muris are associated with protection against papa-
in-induced AAI.
Low-dose T. muris infection protects against acute airway
inflammation in the absence of CD4 T cells.Given that we saw
an increase in lung CD4 Th1 cells following infection with T.
muris, we wanted to test whether these cells were necessary for
protection against papain-induced AAI. T. muris-infected mice
were treated with a depleting monoclonal antibody against CD4
prior to papain challenge (Fig. 5A). Strikingly, T. muris-infected
mice depleted of CD4 cells were protected from papain-induced
AAI, based on a persistent reduction of airway eosinophilia com-
pared to uninfected control mice (Fig. 5B). Gene expression anal-
ysis showed that infected, CD4-depleted mice had a significant
reduction in Ifng expression in the lungs but still maintained in-
FIG2 LungCD4T cells upregulate IFN- expression but not IL-10 during low-doseT.muris infection. (A andB) Frequencies of CD4 lymphocytes expressing
IFN- (A) and IL-10 (B) in the lung ex vivo after polyclonal stimulation. (C) mRNA expression of Tbx21, Ifng, and Il10 (relative to Actb) in IFN- and IFN-
lung CD4 T cells from GREAT mice sorted by fluorescence-activated cell sorting. Data are means SEM, representative of 3 independent experiments (n	
3 to 5 mice per experiment) (A and B) or representative of 2 independent experiments (n	 3mice per experiment) (C). Ctrl, control; Tm, T. muris infected; ns,
not significant; Rel., relative.
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creased expression of Il10 compared to nondepleted mice
(Fig. 5C). These results confirm a role for lung CD4 T cells in
IFN- production following T. muris infection and suggested
that Th1 cell-expressed IFN- is not absolutely required for
infection-induced protection against AAI. Further, these re-
sults confirm that CD4 T cells are not the source of IL-10 in
the lung.
Rag1/mice are partially protected from acute innate im-
munity-mediated airway inflammation during low-dose T.
muris infection. T. muris-infected mice that were CD4 depleted
were protected from AAI despite a significant reduction in Ifng
expression in the lungs of T. muris-infected CD4-depleted mice
compared to nondepletedmice; however, lung Ifng levels were still
elevated compared to uninfected controls, whichmay have repre-
sented lingering effects of IFN- induction in other cell types prior
to CD4 depletion, as IFN- can exhibit positive feedback signaling
(30). Therefore, we next ascertained whether the entire adaptive
immune system was necessary in our experimental model. To do
so, we performed our T. muris infection/papain challenge model
using Rag1/ mice, which lack T cells and B cells but are still
susceptible to innate immunity-mediated type 2 inflammation.
Surprisingly, T. muris-infected Rag1/ mice had a significant
reduction in total BAL fluid cells as well as BAL fluid eosinophils
compared to uninfected Rag1/ mice after papain challenge
FIG 3 Low-dose T. muris infection induces expression of IL-10 in lung myeloid cells. (A) Total lung IL-10 cell frequencies and absolute numbers in Rag1/
Vert-X (IL-10 reporter) mice either uninfected or infected with low-dose T. muris. SSC, side scatter. (B) Frequencies and absolute numbers of live CD45-gated
CD11bCD11c and CD11bCD11c cell populations comprising the total IL-10 cells in the lung. (C to E) Surfacemarker analysis of Ly6G versus Ly6C (C),
Siglec F versus F4/80 (D), andMHC-II versus CD11c (E) of CD11bCD11c IL-10 gated cells. (F) Gating of total CD11cB220 cells and IL-10 frequencies.
Data are means SEM, representative of 3 independent experiments (n	 5 to 6 mice per experiment) (A to F). Ctrl, control; Tm, T. muris infected.
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(Fig. 6A). However, despite a reduction in airway eosinophilia,
histopathological analysis showed that T. muris-infected Rag1/
mice were equally susceptible to mucus overproduction in the
large airways (Fig. 6B). Ifng expression was not induced in the
lungs of T. muris-infected Rag1/ mice after papain challenge,
further confirming CD4 T cells as the likely source (Fig. 6C).
However, we observed a significant increase in lung Il10 expres-
sion following T. muris infection, confirming an innate cell-de-
rived source of IL-10 in the lungs during T. muris infection. These
results suggest that T. muris-induced adaptive immune responses
are important for regulating goblet cell hyperplasia and mucus
production in the lung but are dispensable for inhibiting eosino-
phil infiltration into the airways after papain exposure.
Neutralization of IL-10 activity alters disease in T. muris-
infectedRag1/mice during acute airway inflammation. Since
we observed a consistent upregulation of IL-10 in the lungs of T.
muris-infected C57BL/6 and Rag1/mice, we hypothesized that
blocking IL-10 activitywould restore susceptibility to eosinophilia
in infected Rag1/ mice after papain challenge. To do so, we
injectedmice with anti-IL-10R antibodies every 3 days starting on
day 6 postinfection, before airway challenge (Fig. 7A). Following
induction of acute lung inflammation with papain, we found that
compared to control and IgG1-treatedT.muris-infected (T.muris
IgG1) mice, anti-IL-10R-treated T. muris-infected (T. muris anti-
IL-10R) mice trended toward an increase in total airway cellular
infiltration as measured by total BAL fluid cell counts comprised
of mainly neutrophils (Fig. 7B). However, blockade of IL-10R did
not reverse suppression of eosinophilia. Consistent with our pre-
vious results, histological examination revealed no significant dif-
FIG 4 Low-dose T. muris infection suppresses papain-induced allergic airway inflammation. (A) Experimental time course of intestinal T. muris infection and
airway challenge with papain. (B) Enumerated cecal worm burdens. (C) Total bronchoalveolar lavage (BAL) fluid cell, BAL fluid eosinophil, and lung tissue
eosinophil counts. (D) PAS-stained sections of lungs, visualized using20 magnification. (E) Lung mRNA expression of Il5, Ifng, and Il10 normalized relative
toActb. Rel., relative. (F) Gating of live CD45 lineageCD90 cells, further gated on CD25 and ST2 to identify ILC2 cells in uninfected or T. muris-infected
mice challenged with papain with absolute numbers shown. (G) IL-13 production by ILC2 cells after ex vivo lung cell stimulation after papain exposure. Naïve,
no papain. Data are means SEM, pooled from 3 independent experiments (n	 3 to 15mice per group) (B to G). Sections are representative of 3 independent
experiments (D). Ctrl, control; Tm, T. muris infected; ns, not significant.
FIG 5 Depletion of CD4 T cells does not reverse T. muris-mediated pro-
tection from papain-induced allergic airway inflammation. (A) Experi-
mental time course of CD4 depletion during the infection/airway challenge
model. (B) Bronchoalveolar lavage (BAL) fluid eosinophil counts. (C)
Lung mRNA expression of Cd4, Ifng, and Il10 (relative to Actb). Data are
means  SEM, representative of 2 independent experiments (n 	 3 to 6
mice per experiment) (B and C). Ctrl, control; Tm, T. muris infected; pap,
papain; Rel., relative.
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ferences in terms ofmucus hyperproduction in papain-challenged
mice, with neither worm infection nor IL-10R blockade having an
effect (Fig. 7C). Together, these data show that while IL-10 did not
play a role in limiting eosinophil infiltration in our model, it did
play a role in limiting neutrophil accumulation in the airways
during acute AAI.
Low-dose T. muris infection protects against the HDM
model of murine asthma. We next wanted to test whether intes-
tinal helminth infection could also abrogate the development of
house dust mite (HDM)-induced AAI. HDM antigen, which dis-
plays protease activity similar to that of papain, has been used
extensively as an animal model of asthma. Unlike papain, HDM-
inducedAAI involves priming and challenge phases of exposure to
HDM antigen with a more prominent role for adaptive immune
responses. Thus, we infectedC57BL/6micewithT.muris either 10
days before the sensitization phase (T. muris d10) or on the first
day of sensitization (T. muris d0) (Fig. 8A). We found that after
challengewithHDMantigen, control andT.muris d0mice had an
increase in total BAL fluid cells and eosinophils while T. muris
d10 mice had significantly fewer total cells and eosinophils in
the BAL fluid (Fig. 8B). Histologically, control and T. muris d0
mice after HDM antigen challenge had an increase in cellular in-
filtration around airways as well as evidence of mucus hyperpro-
duction in bronchioles; in contrast, the lungs of T. muris d10
mice largely resemblednaive lungswith a reduction in both airway
cellular infiltration andmucus production (Fig. 8C). Gene expres-
FIG 6 Low-dose infection with T. muris in Rag1/mice partially protects from papain-induced lung inflammation. (A) Total bronchoalveolar lavage (BAL)
fluid cell and BAL fluid eosinophil counts. (B) PAS-stained sections of lungs, visualized using20 magnification. (C) Lung mRNA expression of Ifng and Il10
(relative to Actb). Data are means SEM, representative of 3 independent experiments (n	 4 to 5 mice per experiment) (A to C). Sections are representative
of 3 independent experiments (B). Ctrl, control; Tm, T. muris infected; Rel., relative.
FIG 7 Blockade of IL-10R partially alters lung inflammation in T. muris-infected Rag1/ mice following papain challenge. (A) Time course of low-dose
infection with T. muris and blockade of IL-10R. (B) Total bronchoalveolar lavage (BAL) fluid cell, BAL fluid eosinophil, and BAL fluid neutrophil counts. (C)
PAS-stained sections of lungs, visualized using20magnification. Data aremeans SEM, pooled from 2 independent experiments (n	 6 to 8mice per group)
(B and C). Sections are representative of 2 independent experiments (C). Ctrl, control; Tm, T. muris infected.
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sion analysis of the lungs showed a significant increase in Ifng
expression in both groups of T. muris-infected mice following
HDM antigen challenge (Fig. 8D); there were no significant dif-
ferences foundbetween controlmice and infectedmice in terms of
Il10 gene expression. Based on these results, we conclude that T.
muris-mediated protection from HDM antigen-induced airway
disease likely involves an effect during the early sensitization phase
of the model.
DISCUSSION
Low-dose infections with T. muris cause a localized intestinal Th1
cell response, resulting in parasite persistence in most strains of
wild-type mice (25). Since low-dose T. muris infections have been
shown to induce increased intestinal levels of IFN- and IL-10 (31,
32), we assessed whether levels of these cytokines were also af-
fected distally in the lungs. We found that T. muris infection was
sufficient to significantly increase IFN- and IL-10 expression in
the lung, in the absence of any signs of airway pathology. Our
follow-up analyses determined that T. muris infection-induced
lung IFN-was predominately produced byCD4Th1 cells while
IL-10 was mainly myeloid cell derived. Furthermore, these infec-
tion-induced changes in the lung immune microenvironment
correlated with complete resistance to innate immunity-mediated
type 2 responses to the protease allergen papain.
Our results suggest that both adaptive and innate responses
were required for mediating infection-induced distal suppression
of AAI. IFN- from Th1 cells may inhibit the development of Th2
cell responses during AAI, but its role has been controversial and
context dependent (33–35). It has been reported previously that
IFN- can negatively regulate goblet cell function during AAI (36,
37), a role that is consistent with our results showing a consistent
infection-induced upregulation of lung IFN- correlating with
reductions in goblet cell-derived mucus production during AAI.
In parallel, IL-10 has pleiotropic effects on all immune cells and,
during AAI, can be considered to be protective (38, 39); for exam-
ple, IL-10 can regulate Th2 cell cytokine responses and have a
negative effect on eosinophil function and survival (40–42). To
tease out the individual roles of these cytokines, we showed thatT.
muris-infected Rag1/ mice, which had elevated lung IL-10 in
the absence of lung IFN- responses, were not fully protected
from AAI. In addition, we blocked IL-12, a cytokine that potently
drives IFN- expression, and found that this was not sufficient to
reverse protection fromAAI during T. muris infection (see Fig. S1
in the supplemental material). Thus, infection-induced IFN-
and IL-10 have nonredundant roles in the inhibition of AAI.
Previously, Mohrs et al. showed that infection with a different
intestinal helminth, Heligmosomoides polygyrus bakeri, which in-
duces a mixed Th2/regulatory T (Treg) cell response, results in
FIG 8 Time dependence of low-doseT.muris-mediated suppression of house dustmite (HDM) antigen-induced allergic airway inflammation. (A) Time course
of low-dose infection either before (Tm d10) or concurrent (Tm d0) with intranasal (i.n.) sensitization with HDM antigen. (B) Total bronchoalveolar lavage
(BAL) fluid cell and BAL fluid eosinophil counts. (C) PAS-stained sections of lungs, visualized using20magnification. (D) LungmRNA expression of Ifng and
Il10 (relative toActb). Data aremeans SEM, representative of 3 independent experiments (n	 3 to 5mice per experiment) (B toD). Sections are representative
of 3 independent experiments (C). Ctrl, control; Tm, T. muris infected; nd, not detected; Rel., relative.
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systemic dissemination of Th2 cells to extraintestinal sites, includ-
ing the airways (43); together with our results showing accumula-
tion of Th1 cells in the lung following T. muris infection, this
suggests that specific Th cell-polarized responses can propagate
from the intestine to the lung. In parallel with this Th1 response,
the innate IL-10 cells may represent a heterogeneous population
of immature myeloid cells that expand during low-dose T. muris
infection. Further, our results demonstrate that a prominent sub-
set of these myeloid cells were B220, resembling plasmacytoid
DCs (pDCs); pDCs have been associated with the priming of IL-
10-producing Treg cells (44) but have not been described before
to intrinsically produce IL-10. In the context of cross-mucosal
trafficking, lung DCs can upregulate gut-homing receptors on T
cells to induce migration from the lung to the gut (10). Given that
we saw T. muris antigen-responding Th1 cells in the lung, T cell
migration between the gut and the lung may actually be bidirec-
tional. However, it remains to be determined whether these adap-
tive and innate cells are intestinally derived cells that traffic to the
lung or are instead locally induced de novo in the lung mucosa
following systemic dissemination of helminth antigens. Addition-
ally, future studies should determine whether T. muris infection
affects hematopoiesis in the bone marrow, since IFN- is known
to profoundly impact hematopoietic progenitor cells and eosino-
phil differentiation (45).
It has previously been shown that intestinalH. polygyrus infec-
tion can also suppress murine models of asthma, primarily
through the induction of Treg cells via a helminth-secreted trans-
forming growth factor beta (TGF-
) analog (46). Further, soluble
excretory/secretory products fromH. polygyrus, when coadminis-
tered with allergens intranasally, are sufficient in suppressing type
2 responses (47). In contrast, we found that our model of intesti-
nal T. muris infection modulating lung immune responses does
not depend on Treg cell responses when considering our CD4
depletion results and after quantifying lung Treg cells following
papain exposure (see Fig. S2 in the supplemental material). H.
polygyrus-mediated suppression of AAI is dependent on IL-10
(48); although we found a consistent upregulation of IL-10 in the
lung during T. muris infection, innate IL-10 in infected Rag1/
mice was not sufficient to fully protect against AAI. Instead, our
results suggest nonredundant roles for both Th1 cells and innate
myeloid cells in T. muris infection-mediated protection from type
2 airway inflammation. Thus, we hypothesize that the Th1 cell-
associated response to T. muris gets misdirected to the lungs and,
in the absence of appropriate antigen, becomes self-limiting by
inducing immunoregulatory responses involving IL-10, resulting
in bystander immunosuppression in the local airway mucosa. In
parallel to these responses, it has been shown that chronicT.muris
infection causes alterations in the intestinal microbiota composi-
tion and metabolome (49) which may potentially play a role in
mediating gut-to-lung immune cross talk, since this has been de-
scribed to occur during H. polygyrus infection (50).
Finally, we assessed the impact of our Th1 cell-driven infection
model on an AAI model more relevant to human asthma, with a
significant adaptive immune component. Complete protection
from HDM antigen-induced AAI occurred only in mice infected
with T. muris prior to sensitization, suggesting that the timing of
the infection is critical in establishing protection against asthma.
Consistent with our data on early type 2 responses to papain, this
likely involves a critical effect of the infection on the early phases of
type 2 inflammation. This may partially explain why treatment of
allergic rhinitis patients with Trichuris suis ova has been found to
be ineffective during the peak of allergic symptoms (51). Broadly,
this suggests that Th1 cell-driven intestinal inflammation and as-
sociated immunoregulatory responses are effective only as a pro-
phylactic means to suppress type 2 responses, as opposed to being
therapeutic.
In summary, we have shown that an intestinally restricted, Th1
cell-driven infection can potently suppress the development of
innate immunity-mediated type 2 responses in the lung, in a tem-
porally dependent manner. The cellular mechanisms involved
display a complex, multifaceted means of host immunomodula-
tion that involves both innate and adaptive immunity and spans
distinctmucosal tissues. These converging immune pathwaysmay
highlight novel avenues of better understanding cross-mucosal
immune regulation.
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